๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HER 2 Negative Breast Cancer

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cediranib, Ceralasertib, Olaparib Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer NCT07658183Phase 21 site๐Ÿ“ Shanghai Shanghai Best-Link Bioscience, LLC ยท Tests: BL0175 Injection, BL0175 Injection Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites๐Ÿ“ Chicago๐Ÿ“ Chicago๐Ÿ“ Chicago Northwestern University ยท Tests: elacestrant, palbociclib, abemaciclib, ribociclib The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer NCT06452706Phase 216 sites๐Ÿ“ Bozhou๐Ÿ“ Chuzhou๐Ÿ“ Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharโ€ฆ ยท Tests: TQB2102 for injection Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Beverly Hills Puma Biotechnology, Inc. ยท Tests: Alisertib, Endocrine therapy Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites๐Ÿ“ St Leonards๐Ÿ“ Nedlands๐Ÿ“ Perth RayzeBio, Inc. ยท Tests: RYZ211/212 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites๐Ÿ“ Lake Mary๐Ÿ“ Sarasota๐Ÿ“ Cincinnati Edgewood Oncology Inc. ยท Tests: BTX-A51 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ San Diego RayzeBio, Inc. ยท Tests: RYZ101, Standard of Care Endocrine Therapy Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer NCT06462092Phase 1, Phase 21 site๐Ÿ“ Huizhou Guangzhou Medical University ยท Tests: Sacituzumab Govitecan, Pemetrexed NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites๐Ÿ“ Sankt Gallen๐Ÿ“ Genolier๐Ÿ“ Winterthur Swiss Cancer Institute ยท Tests: Doxycyclin A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates NCT07520760Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Eribulin in Combination with Anlotinib FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Port Saint Lucie Regor Pharmaceuticals Inc. ยท Tests: RGT-419B, RGT-419B in combination with hormonal therapy A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor NCT07612891Phase 1, Phase 21 site๐Ÿ“ Shanghai Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-6452 A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) NCT04333706Phase 1, Phase 23 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Gainesville University of Southern California ยท Tests: Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) NCT07541079Phase 38 sites๐Ÿ“ Fountain Valley๐Ÿ“ Stockton๐Ÿ“ Washington D.C. Genentech, Inc. ยท Tests: Giredestrant Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) NCT05898399Phase 1, Phase 227 sites๐Ÿ“ Grand Rapids๐Ÿ“ New York๐Ÿ“ Oklahoma City Artios Pharma Ltd ยท Tests: ART6043, Olaparib BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer NCT06756932Phase 114 sites๐Ÿ“ Iowa City๐Ÿ“ Houston๐Ÿ“ Seattle BeOne Medicines ยท Tests: BGB-21447, Fulvestrant, BGB-43395 S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites๐Ÿ“ Anchorage๐Ÿ“ Anchorage๐Ÿ“ Anchorage SWOG Cancer Research Network ยท Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Quesโ€ฆ Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy NCT02945579NA8 sites๐Ÿ“ Gilbert๐Ÿ“ Jacksonville๐Ÿ“ Honolulu M.D. Anderson Cancer Center ยท Tests: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Iโ€ฆ Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive๏ผŒ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer NCT07796880Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Culmerciclib, Aromatase Inhibitor (AI) Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites๐Ÿ“ St Louis๐Ÿ“ East Providence๐Ÿ“ Nashville AstraZeneca ยท Tests: Camizestrant, Atirmociclib Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site๐Ÿ“ Shanghai Wenjin Yin ยท Tests: QL1706, CDK4/6 inhibitor, Fulvestrant
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy